The clinical significance of soluble human leukocyte antitgen class-I, ICTP, and RANKL molecules in multiple myeloma patients

Schütt, Philipp; Rebmann, Vera; Brandhorst, Dieter; Wiefelspütz, Johannes; Ebeling, Peter R.; Opalka, Bertram; Seeber, S.; Nowrousian, Mohammad R.; Möritz, Thomas; Grosse‐Wilde, H.

doi:10.1016/j.humimm.2008.01.006

Cited by 17 publications

(10 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…83 The RANKL/OPG ratio has been found to correlate with OS in MM. This result has not been confirmed in all reported studies to date, 63,69,83,84 may be due to differences in patient populations and/or therapies administered. Further studies are needed before measurement of serum RANKL and OPG levels in the everyday clinical setting should be considered.…”

Section: Correlations Of Bone Turnover Markers With Myeloma Activity mentioning

confidence: 80%

“…48,51 Markers of bone remodeling have also correlated with wellcharacterized markers of disease activity, such as b2-microglobulin and interleukin-6 48,51,55,64 and also with overall survival (OS). 44,46,48,52,68,69 Fonseca et al showed that the median survival was 4.1 and 3.5 years for patients who received CC and had low or high ICTP levels, respectively (P ¼ 0.02). 48 Jakob et al also reported that ICTP is a prognostic factor for OS in MM patients treated with CC (Po0.03), whereas urinary NTX was only of borderline prognostic value (P ¼ 0.05).…”

Section: Correlations Of Bone Turnover Markers With Myeloma Activity mentioning

confidence: 99%

See 1 more Smart Citation

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

et al. 2010

View full text Add to dashboard Cite

Lytic bone disease is a frequent complication of multiple myeloma (MM). Lytic lesions rarely heal and X-rays are of limited value in monitoring bone destruction during antimyeloma or anti-resorptive treatment. Biochemical markers of bone resorption (amino-and carboxy-terminal cross-linking telopeptide of type I collagen (NTX and CTX, respectively) or CTX generated by matrix metalloproteinases (ICTP)) and bone formation provide information on bone dynamics and reflect disease activity in bone. These markers have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity and response to anti-resorptive treatment in MM. Urinary NTX, serum CTX and serum ICTP are elevated in myeloma patients with osteolytic lesions and correlate with advanced disease stage. Furthermore, urinary NTX and serum ICTP correlate with risk for skeletal complications, disease progression and overall survival. Bone markers have also been used for the early diagnosis of bone lesions. This International Myeloma Working Group report summarizes the existing data for the role of bone markers in assessing the extent of MM bone disease and in monitoring bone turnover during anti-myeloma therapies and provides information on novel markers that may be of particular interest in the near future.

show abstract

Section: Correlations Of Bone Turnover Markers With Myeloma Activity mentioning

confidence: 80%

Section: Correlations Of Bone Turnover Markers With Myeloma Activity mentioning

confidence: 99%

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Because of these functional properties, both molecules appear to be promising markers for the prediction of overall or progression-free survival in cancer patients. So far a comparative analysis of these two markers has been performed for patients with multiple myeloma and malignant lymphoma [25,27,30]. Here, increased serum levels of sHLA-I and sHLA-G were associated with a poor prognosis and disease progression.…”

Section: Discussionmentioning

confidence: 99%

Prognostic relevance of soluble human leukocyte antigen–G and total human leukocyte antigen class I molecules in lung cancer patients

Schütt

Switala

et al. 2010

Human Immunology

Self Cite

View full text Add to dashboard Cite

“…Such elevated levels of sHLA were even proposed to serve as indicators of poor prognosis (11,17), yet their bound peptidomes have never been analyzed before. We postulated that if indeed a significant portion of the plasma sHLA molecules are actually released from the diseased cells, and if these molecules carry with them their original peptide cargo, then analysis of the sHLA peptidomes may provide useful information about the tumor cells and an ideal source for disease biomarkers, serving as a high-sensitivity diagnostics for diseases, such as cancer.…”

mentioning

confidence: 99%

Soluble plasma HLA peptidome as a potential source for cancer biomarkers

Bassani-Sternberg

Barnea

Beer

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

120

133

View full text Add to dashboard Cite

The HLA molecules are membrane-bound transporters that carry peptides from the cytoplasm to the cell surface for surveillance by circulating T lymphocytes. Although low levels of soluble HLA molecules (sHLA) are normally released into the blood, many types of tumor cells release larger amounts of these sHLA molecules, presumably to counter immune surveillance by T cells. Here we demonstrate that these sHLA molecules are still bound with their authentic peptide repertoires, similar to those of the membranal HLA molecules (mHLA). Therefore, a single immunoaffinity purification of the plasma sHLA molecules, starting with a few milliliters of patients' blood, allows for identification of very large sHLA peptidomes by mass spectrometry, forming a foundation for development of a simple and universal blood-based cancer diagnosis. The new methodology was validated using plasma and tumor cells of multiple-myeloma and leukemia patients, plasma of healthy controls, and with cultured cancer cells. The analyses identified thousands of sHLA peptides, including some cancer-related peptides, present among the sHLA peptidomes of the cancer patients. Furthermore, because the HLA peptides are the degradation products of the cellular proteins, this sHLA peptidomics approach opens the way for investigation of the patterns of protein synthesis and degradation within the tumor cells.

show abstract

The clinical significance of soluble human leukocyte antitgen class-I, ICTP, and RANKL molecules in multiple myeloma patients

Cited by 17 publications

References 48 publications

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

Prognostic relevance of soluble human leukocyte antigen–G and total human leukocyte antigen class I molecules in lung cancer patients

Soluble plasma HLA peptidome as a potential source for cancer biomarkers

Contact Info

Product

Resources

About